Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences to $73 from $78 and keeps a Hold rating on the shares. The analyst said its investor day set 2023 financial guidance and announced a CEO succession plan. He continues to believe the company is the market innovator in structural heart and likely a long-term winner, but it continues to be hindered by slow-growth markets that have been impacted by staffing and COVID.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $92 from $99 at Citi
- Edwards Lifesciences price target lowered to $92 from $98 at Morgan Stanley
- Edwards Lifesciences to host investor meeting
- Edwards Lifesciences backs FY22 adjusted EPS view $2.40-$2.50, consensus $2.46
- Edwards Lifesciences sees FY23 adjusted EPS $2.45-$2.60, consensus $2.53
